REPL News and Press, Replimune Group Inc.

WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at ...

2026-02-20 23:46:09 ET ... Read the full article on Seeking Alpha For further details see: Replimune: Multiple Shots On Goal But A High Risk Binary Approaches

2026-02-05 06:15:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for REPL on February 5, 2026 11:49AM ET. The previous analyst recommendation was Overweight. REPL was trading at $7 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2026-02-03 23:55:28 ET More on Replimune Group Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Replimune Group GAAP EP...

WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a b...

2026-01-14 19:15:59 ET Replimune Group, Inc. (REPL) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Confe...

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44 th Annual J.P. Morgan ...

2025-12-16 09:19:08 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 11/14/2025. The 13F portfolio value in...

2025-11-27 07:20:44 ET Introduction As the year comes to an end, we must be thankful for the therapies that are in late clinical stages. Most importantly, patients are set to benefit immensely. But nearly every trial candidate has implications beyond just patients. The approval of a...

2025-11-26 15:13:03 ET More on Markets The 'Real' Economy Is In Real Trouble Boomer Blues, Not Gen Z? SPYI Vs. SPY: The Case For Covered Calls In Two Charts Mixed signals as S&P 500’s December strength weakens in recent decade Sociét&#...